The novel application of TNFR2 as a predictive biomarker for CKD progression underscores the relevance of this method in clinical settings and highlights the need for further exploration of TNF-α-targeted therapies to mitigate renal damage [20, 21]. This evidence concerns the gene TNFRSF1B and chronic kidney disease.